Wall Street analyst estimates for Moleculin Biotech, Inc. (MBRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.44 | ||
| 2026-08-13 | $-1.40 | $-1.55 | +9.7% |
| 2026-05-14 | $-3.54 | $-1.69 | -109.5% |
| 2026-03-20 | $2.61 | $-7.77 | +133.6% |
| 2025-11-13 | $-17.02 | $-5.00 | -240.4% |
| 2025-08-12 | $-12.25 | $-9.75 | -25.6% |
| 2025-05-14 | $-17.25 | $-17.75 | +2.8% |
| 2025-03-24 | $-6.25 | $-1.54 | -305.8% |
Valuation Ratios
| Price / Book | 0.37 |
| EV / EBITDA | 0.10 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $6162 | $18000 | $68000 | $185000 | 0 | 0 | 0 | 0 | 0 | $90000 |
| Gross Profit | -$6162 | -$18000 | -$68000 | -$185000 | 0 | 0 | 0 | 0 | 0 | -$90000 |
| Research & Development | $1.5M | $4.5M | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M |
| Selling, General & Admin | $2.4M | $4.1M | $5.3M | $6.3M | $6.8M | $8.4M | $11.5M | $10.0M | $8.8M | $9.1M |
| Operating Expenses | $3.9M | $8.7M | $15.0M | $17.3M | $19.7M | $23.0M | $30.6M | $29.6M | $26.6M | $25.1M |
| Operating Income | -$3.9M | -$8.7M | -$15.0M | -$17.5M | -$19.7M | -$23.0M | -$30.6M | -$29.6M | -$26.6M | -$25.1M |
| EBITDA | -$3.9M | -$8.6M | -$15.0M | -$13.2M | -$19.5M | -$15.7M | -$28.9M | -$29.6M | -$21.6M | -$33.5M |
| Interest Expense | $43214 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$3.9M | -$9.8M | -$11.9M | -$13.4M | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M |
| Income Tax | 0 | 0 | 0 | -$229000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.9M | -$9.8M | -$11.9M | -$13.2M | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M |
| EPS | $-900.00 | $-1188.07 | $-1031.54 | $-729.63 | $-661.00 | $-221.77 | $-380.51 | $-376.71 | $-189.14 | $-28.42 |
| EPS (Diluted) | $-900.00 | $-1188.07 | $-1031.54 | $-729.63 | $-661.00 | $-221.77 | $-380.51 | $-376.71 | $-189.14 | $-28.42 |
| Shares Outstanding (Diluted) | $4367 | $8252 | $11512 | $18098 | $26255 | $71669 | $76278 | $79024 | $137720 | $1.2M |
Price
| Price | $0.74 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADAP · AIMD · APLM · ATHA · BLRX · CTXR · ICU
Explore sector: Healthcare · Biotechnology
More sections of MBRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks